DENVER, Colo. (247marketnews.com) -- The markets are producing a striking mix of catalysts, with NeOnc (NASDAQ:NTHI), Kraig Biocraft Laboratories (OTCQB:KBLB), Profusa (NASDAQ:PFSA), Sky Quarry (NASDAQ:SKYQ), Glucotrack (NASDAQ:GCTK) and Greenland Mines (NASDAQ:GRML) all generating fresh developments.
NeOnc Technologies Holdings: Wall St Big Buy Rating on Clinical Catalyst
NeOnc (NASDAQ:NTHI) is entering a potentially pivotal period after Roth Capital analyst Jonathan Aschoff initiated coverage with a Buy rating and $20 price target, according to the research referenced in the company's investor materials. Roth's model centers on NEO100 for recurrent IDH1-mutant high-grade glioma and NEO212 for recurrent glioblastoma, with the firm's valuation work incorporating substantial clinical-development risk.
The underlying clinical story has become substantially more tangible. In August, NeOnc reported that its Phase 2a NEO100 study achieved six-month progression-free survival of 48.9%, compared with a prespecified 20% benchmark, with median overall survival of 26.09 months among the 24-patient cohort. The company said it intended to engage the FDA regarding a registrational development path.
Management has continued to put capital behind the program. NeOnc priced a $15 million registered direct offering in September at $4.20 per share, accompanied by warrants, while CEO Amir Heshmatpour subsequently reported additional open-market purchases. The company said executives had purchased approximately $629,000 of stock following the NEO100 data announcement.
The next major question is whether the encouraging Phase 2a results can translate into a regulatory pathway and pivotal development. The company is also advancing NEO212, while Roth's research points to potential pivotal-trial activity in 2026. Those milestones remain dependent on regulatory discussions, trial design, financing and ultimately clinical results—not simply the analyst's forecast.
Kraig Biocraft Laboratories: Project Atlas Enters Its Next Phase
Kraig Labs (OTCQB:KBLB) has announced completion of what it calls the foundational Atlas Gene Library, reporting that every planned Project Atlas transgene has now been integrated into living commercial silkworm hosts. The milestone moves the company's research program from assembling individual genetic building blocks toward breeding and evaluating combinations of those technologies.
The next stage centers on establishing stable homozygous breeding lines for the individual Atlas transgenes. According to Kraig, those lines could ultimately enable systematic testing of more than 200 potential genetic pairings, giving researchers a broad range of configurations to evaluate for strength, toughness, flexibility and other material characteristics.
Dr. Xiaoli Zhang, Chief Scientist of Kraig Labs, described the milestone as “a defining milestone for Project Atlas,” adding that the company is now shifting its focus toward homozygous lines and evaluation of the more than 200 configurations the library could enable. The quote is particularly significant because it describes the transition from foundational genetics work to the next stage of experimentation.
The commercial question is ultimately what these experiments produce outside the laboratory. Kraig is simultaneously pursuing expansion of its recombinant spider-silk production operations, creating a two-track story: scaling current production while developing potentially more advanced generations of engineered silk. The company's announcement is therefore less about an immediate commercial product launch and more about expanding the technological toolkit available for future fibers.
Profusa: Lumee Moves Closer to the European Finish Line
Profusa (NASDAQ:PFSA) has delivered a potentially important regulatory update for its Lumee Oxygen Platform, announcing a positive decision from GMED regarding certification of its quality-management system to ISO 13485. Profusa expects the certification to be completed in early October while continuing the remaining conformity-assessment work required under the European Union's Medical Device Regulation.
CEO Ben Hwang called the development “a significant milestone for Profusa” and said the company had made progress strengthening its quality-management system and addressing GMED's observations. The distinction is critical, however: ISO 13485 certification is not the same thing as CE marking. Profusa's regulatory information currently states that the Lumee Oxygen Platform's CE certification remains “under review with GMED SAS.”
Lumee is designed as a subcutaneous tissue-oxygen monitoring system capable of continuously measuring local tissue oxygen levels. The platform is intended to provide clinicians with objective tissue-perfusion information that could support treatment decisions and patient monitoring.
That makes the remaining GMED process the key variable. Successful completion could support issuance of the applicable MDR certificate and subsequent CE marking, but Profusa itself cautions that there is no assurance regarding the timing or outcome of the remaining assessment activities. For the market, the story is therefore a regulatory progression rather than a completed approval—and the next GMED milestone could determine whether today's progress becomes a commercial inflection point.
SKYO:Nevada Refinery Restart as Energy Infrastructure Takes Center Stage
Sky Quarry (NASDAQ:SKYQ) has moved from preparation to operations at its Eagle Springs Refinery near Ely, Nevada, after receiving an air permit from the Nevada Division of Environmental Protection. The refinery is operated through wholly owned subsidiary Foreland Refining Corporation, and Sky Quarry says approximately $300,000 in repairs and upgrades were completed before the restart.
The facility has a stated nameplate capacity of approximately 5,000 barrels of crude oil per day, although that figure represents capacity rather than current production. Sky Quarry says it has approximately 15,000 barrels of crude oil inventory on hand and expects additional supply as operations progress. That distinction makes the next operational updates particularly important.
“Receiving this permit and restarting Nevada's only crude oil refinery is a major step for Sky Quarry,” Interim CEO Marcus Laun said. He added that the company's objective is to ramp Eagle Springs toward its full operating potential and increase the role of Nevada-refined products in the region's supply.
The bigger narrative extends beyond the refinery itself. Sky Quarry remains engaged with Nevada fuel-supply initiatives and continues discussions surrounding its PR Spring opportunity in Utah and potential use of its 7-megawatt power-generation capacity. The immediate market test, however, is straightforward: how quickly and efficiently can Eagle Springs move from a restart to sustained commercial operations?
Glucotrack: Lōkahi Turns Its Asset-Discovery Engine into a Business
Glucotrack (NASDAQ:GCTK) is developing a second narrative alongside its diabetes-monitoring technology through subsidiary Lōkahi Therapeutics, where the proprietary ai² PIPELINE platform has secured its first external fee-for-service customer. Innovate GBM, a nonprofit focused on accelerating new treatments for glioblastoma and other brain tumors, has engaged two project teams to identify and evaluate potential therapeutic assets for licensing and development.
The significance is less about one individual drug candidate and more about the business model. Lōkahi says ai² PIPELINE was previously an internal asset-discovery engine operating through university collaborations. With Innovate GBM becoming its first external sponsor, the company is testing whether the platform can become a service capable of generating revenue while expanding the number of therapeutic opportunities it evaluates.
CEO Erik Emerson described the move as “the next step forward for the ai² PIPELINE,” saying the platform is moving from a company-led initiative toward a model that outside organizations can use. Innovate GBM's Kush Thukral similarly characterized the system as a “disciplined, capital-efficient way to search systematically for overlooked brain tumor assets.”
At the same time, Glucotrack is continuing to fund its broader strategy. The company announced pricing of a roughly $3.1 million gross public offering, involving common shares and pre-funded warrants at approximately $2.04 per share-equivalent, with the offering expected to close subject to customary conditions.
Greenland Mines Strengthens Balance Sheet
Greenland Mines Ltd. (NASDAQ:GRML) has strengthened its balance sheet with more than $42 million in new capital, raised from existing investors through a registered direct offering and exercise of previously issued warrants. The company says the financing substantially funds its planned exploration and development programs through targeted 2027 milestones, prompting it to terminate its at-the-market offering facility. “Now it’s about execution,” President Dr. Bo Møller Stensgaard said, highlighting the company’s focus on advancing its Greenland portfolio.
The financing arrives alongside completion of Greenland Mines’ 2026 field program at the Sarfartoq Neodymium-Praseodymium (NdPr) Rare Earth Project in southwest Greenland. Over roughly three weeks, the company conducted geological and structural mapping, drone-supported surveying and systematic rock sampling across priority areas of the Sarfartoq Carbonatite Complex. Samples are expected to be submitted to a Canadian laboratory for rare-earth analysis, while environmental baseline work continued and the company winterized its camp for a potential restart ahead of the 2027 field season.
The centerpiece is Sarfartoq’s existing ST1 Mineral Resource of approximately 12.2 million tons grading 1.32% TREO. An independent Initial Assessment reported a high-case pre-tax NPV8 of approximately $2.05 billion and a pre-tax IRR of 118.6%, although those figures relate to the existing project assessment and should not be interpreted as a guarantee of future economics. Importantly, the latest field campaign is still early-stage: assay results have not yet been received, and Greenland Mines cautions that the newly sampled areas have not established grade, continuity, tonnage or economic viability. With funding secured and Sarfartoq's field program complete, the company's story now shifts squarely toward drilling, technical work, exploration results and execution of its 2027 milestones.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.